JAB-8263 not checked
Jacobio Pharmaceuticals Co., Ltd.
FollowEvery change as it happens, and a Monday email
Trials
2 active
3 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Rheumatoid Arthritis (RA), NSCLC, SCLC, CRPC, ESCC, Ovarian Carcinoma, AML, MF and 1 more
- Main trialPhase 2
- “This study is an open-label, multi-center Phase IIa study. The study is divided into two phases. The first phase is a safety exploration phase. Participants with active rheumatoid arthritis were enrolled and treated with JAB-8263 alone for 4 weeks. The purpose is to evaluate the safety, PK/PD characteristics and preliminary effectiveness of JAB-8263 in participants with active RA.”In the company’s words, NCT07684157 on ClinicalTrials.gov
Other drugs for Rheumatoid Arthritis (RA)
- TLL-018Hangzhou Highlightll Pharmaceutical Co., Ltd · Phase 3
- AdmilparantBristol Myers Squibb · Phase 3
- UpadacitinibAbbVie · Phase 3
- AbataceptBristol Myers Squibb · Phase 3
- AdalimumabAbbVie · Phase 3
- AnakinraSwedish Orphan Biovitrum · Phase 3
Coming up2
- 30 Jun 2027Phase 2 trial completes · ClinicalTrials.gov
- Jan 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 30 Jun 2027 | A Phase IIa Study of JAB-8263 in Patients With Active Rheumatoid Arthritis | |
| Phase 1/2Recruiting | Jan 2028 | A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors | |
| Phase 1Completed | 31 Oct 2024 | A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026